Alkermes plc - Asset Resilience Ratio
Alkermes plc (8AK) has an Asset Resilience Ratio of 3.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 8AK strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Alkermes plc's Asset Resilience Ratio has changed over time. See 8AK equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Alkermes plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Alkermes plc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €160.31 Million | 3.76% |
| Total Liquid Assets | €160.31 Million | 3.76% |
Asset Resilience Insights
- Limited Liquidity: Alkermes plc maintains only 3.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Alkermes plc Industry Peers by Asset Resilience Ratio
Compare Alkermes plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Alkermes plc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Alkermes plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.03% | €199.65 Million ≈ $233.41 Million |
€2.49 Billion ≈ $2.91 Billion |
-14.38pp |
| 2024-12-31 | 22.40% | €460.52 Million ≈ $538.40 Million |
€2.06 Billion ≈ $2.40 Billion |
+7.61pp |
| 2023-12-31 | 14.79% | €316.02 Million ≈ $369.46 Million |
€2.14 Billion ≈ $2.50 Billion |
-1.30pp |
| 2022-12-31 | 16.09% | €315.99 Million ≈ $369.43 Million |
€1.96 Billion ≈ $2.30 Billion |
+6.27pp |
| 2021-12-31 | 9.82% | €198.77 Million ≈ $232.38 Million |
€2.02 Billion ≈ $2.37 Billion |
-5.12pp |
| 2018-12-31 | 14.93% | €272.53 Million ≈ $318.62 Million |
€1.83 Billion ≈ $2.13 Billion |
+1.46pp |
| 2017-12-31 | 13.48% | €242.21 Million ≈ $283.17 Million |
€1.80 Billion ≈ $2.10 Billion |
-4.53pp |
| 2016-12-31 | 18.01% | €310.86 Million ≈ $363.42 Million |
€1.73 Billion ≈ $2.02 Billion |
-1.05pp |
| 2015-12-31 | 19.06% | €353.67 Million ≈ $413.48 Million |
€1.86 Billion ≈ $2.17 Billion |
-2.16pp |
| 2014-12-31 | 21.21% | €407.10 Million ≈ $475.95 Million |
€1.92 Billion ≈ $2.24 Billion |
+8.87pp |
| 2013-12-31 | 12.34% | €194.67 Million ≈ $227.59 Million |
€1.58 Billion ≈ $1.84 Billion |
-- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more